ClinicalTrials.gg
Status unknownNCT04480333NEUROSIVIRUpdated Jul 21, 2020

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

A Phase 1 interventional study of Drug: NA-831 - 0.10 mg/kg and Placebo- 0.10 mg/kg in Covid19, Corona Virus Infection and Severe Acute Respiratory Syndrome, sponsored by Biomed Industries, Inc.. Status unknown at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-07-21.

Sponsored by Biomed Industries, Inc. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Planned enrollment
37th of 40
45 · median 283
Started
2020
with 26 others
Phase 1
3 of 40
1 open now
Registered
14th of 40
by date
Lead sponsor
1 of 40
Biomed Industries, Inc.

Among the 40 studies testing remdesivir in COVID-19, this one is the 37th largest by planned enrollment, is one of 27 that started in 2020, is one of 3 in phase 1, and was the 14th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.

Read the detailed description

It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response. Neurotropism is one common feature of Covid-19. Such neuro-invasive propensity of Covid-19 has been documented almost for all the Beta-coronaviruses including SARS-CoV and MERS-CoV.

Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. It was observed that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimer's disease.

NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its promising safety and efficacy in Phase 2A for the treatment of early onset of Alzheimer's disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects. NA-831 in oral formulation exhibits predictable pharmacokinetics including dose-dependent exposure linearity and low variability.

Based on animal studies, NA-831 can provide effective interventions during the severe acute respiratory syndrome, and provide appropriate rehabilitation measures afterwards.

Remdesivir (GS-5734) intravenous formulation has been approved by the FDA under the emergency use authorization for potential treatment of severe cases of Covid-19.

It was found the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection early in disease. Delivering drugs directly to the primary site of infection with a nebulizer, inhaled nanoparticle formulation may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug.

The study is designed to evaluate the safety, tolerability and pharmacokinetics of a new nanoparticle formulation of Remdesivir (GS-5734) and combination therapy with NA-831 in healthy volunteers.

03

Conditions studied

  • Covid19
  • Corona Virus Infection
  • Severe Acute Respiratory Syndrome
  • Severe Acute Respiratory Infection
  • Severe Acute Respiratory Syndrome (SARS) Pneumonia
  • Severe Acute Respiratory Syndrome of Upper Respiratory Tract
  • Neurodegeneration
  • Neuroinflammatory Response

Keywords

  • Covid-19
  • Corona Virus Infection
  • Severe Acute Respiratory Syndrome
  • Severe Acute Respiratory Infection
  • Severe Acute Respiratory Syndrome (SARS) Pneumonia
  • Severe Acute Respiratory Syndrome of Upper Respiratory Tract
  • Neurodegeneration
  • Neuroinflammation
  • Cognitive decline
04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers, aged 21 to 50 years old, men or women.
  2. Subjects negative for (HIV antibody screen), virus surface Antigen (HBsAg) and virus (HCV antibody screen).
  3. Subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact.
  4. Subjects who give written approved by the Internal Review Board governing the site.
  5. Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. Normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not as judged by the Investigator and acceptable for study entry.
  6. Accessible vein in the forearm for blood collection.
  7. Female subjects of may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission.
  8. Female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.
  9. Both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).

Exclusion criteria

EXCLUSION CRITERIA:

  1. Subject previously diagnosed with COVID-19 or had been issued with a quarantine order by the Center of Disease Control (CDC).
  2. Presence of acute infection in the preceding 14 days, or presence of a temperature ≥ 100.0 ˚F (oral or tympanic temperature assessment), or acute symptoms of any severity on the scheduled date of admission.
  3. History of severe drug and / or food allergies and / or known allergies to the trial product or its components.
  4. Female subject who is pregnant or breast-feeding.
  5. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, , or disorders.
  6. Any neurological disease or history of significant neurological disorder (e.g. meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  7. Evidence of anemia (HB \< 10 g/dL) or any other significant active hematological disease, or having donated > 450 mL of blood within the past three (3) months.
  8. Participation or planned participation in a study involving the administration of an compound within the past four (4) months or during this study period.
  9. Receipt of immunoglobulins and/or any blood products within nine (9) months of study enrolment or planned administration of any of these products during the study period.
  10. Evidence of or C or by laboratory testing.
  11. A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
  12. Administration of any licensed vaccine within 30 days before the first study vaccine dose.
  13. Both male (if he has a partner of ) and female subjects (of childbearing potential) who are unwilling to use adequate or practice abstinence throughout the duration of the study (up to 84 days post-dosing).
  14. Any condition that, in the opinion of the Investigator, would complicate or compromise the study or well-being of the subject.

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Drug: NA-831 - 0.10 mg/kg

    3 Subjects will take inhaled formulation of NA-831 once a day for 5 days

    Drug: Drug: NA-831 - 0.10 mg/kg

  • Placebo comparator
    Comparable Placebo- 0.10 mg/kg

    3 subjects will take inhaled formulation of placebo once a day for 5 days

    Drug: Placebo- 0.10 mg/kg

  • Experimental
    Drug: NA-831 - 0.20 mg/kg

    6 Subjects will take inhaled formulation of NA-831 once a day for 5 days

    Drug: Drug: NA-831 - 0.20 mg/kg

  • Placebo comparator
    Comparable Placebo- 0.20 mg/kg

    3 subjects will take inhaled formulation of placebo once a day for 5 days

    Drug: Placebo- 0.20 mg/kg

  • Experimental
    Drug: GS-5734 - 1.00 mg/kg

    3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days

    Drug: Drug: GS-5734 - 1.00 mg/kg

  • Placebo comparator
    Comparable Placebo- 1.00 mg.kg

    3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days

    Drug: Placebo- 1.00 mg/kg

  • Experimental
    Drug: GS-5734 - 2.00 mg/kg

    6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days

    Drug: Drug: GS-5734 - 2.00 mg/kg

  • Placebo comparator
    Comparable Placebo - 2.00 mg/kg

    3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days

    Drug: Placebo- 2.00 mg/kg

  • Experimental
    Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)

    3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days

    Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)

  • Placebo comparator
    Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg

    3 Subjects - inhaled formulation of placebo once/day for 5 days

    Combination Product: Placebo 0.10 mg + 1.00 mg/kg

  • Experimental
    Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)

    6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days

    Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)

  • Placebo comparator
    Placebo- 0.20 mg/kg + 2.00mg/kg

    3 Subjects- inhaled formulation of placebo once/day for 5 days

    Combination Product: Placebo 0.20 mg + 2.00 mg/kg

Interventions

  • DrugDrug: NA-831 - 0.10 mg/kg

    Drug page: cyclo(prolylglycyl)

    NA-831 in nanoparticle inhalation formulation

    Also known as: NA-831 is a neuroprotective and neurogenesis drug

  • DrugPlacebo- 0.10 mg/kg

    Placebo in nanoparticle inhalation formulation

    Also known as: Placebo Comparator

  • DrugDrug: NA-831 - 0.20 mg/kg

    Drug page: cyclo(prolylglycyl)

    NA-831 in nanoparticle inhalation formulation

    Also known as: NA-81 is a neuroprotective drug

  • DrugPlacebo- 0.20 mg/kg

    Placebo in nanoparticle inhalation formulation

    Also known as: Placebo Comparator

  • DrugDrug: GS-5734 - 1.00 mg/kg

    Drug page: Remdesivir

    GS-5734 in nanoparticle inhaled formulation

    Also known as: GS-5734 (Remdesivir) is an antiviral drug

  • DrugPlacebo- 1.00 mg/kg

    Placebo in nanoparticle inhalation formulation

    Also known as: Placebo Comparator

  • DrugDrug: GS-5734 - 2.00 mg/kg

    Drug page: Remdesivir

    GS-5734 in nanoparticle inhaled formulation

    Also known as: GS-5734 (Remdesivir) is an anti-viral drug

  • DrugPlacebo- 2.00 mg/kg

    Placebo in nanoparticle inhaled formulation

    Also known as: Placebo Comparator

  • Combination productDrugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)

    Drug pages: cyclo(prolylglycyl) · Remdesivir

    The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation

    Also known as: Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug

  • Combination productPlacebo 0.10 mg + 1.00 mg/kg

    The combined placebo are in nanoparticle inhaled formulation

    Also known as: Placebo Comparator

  • Combination productDrugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)

    Drug pages: cyclo(prolylglycyl) · Remdesivir

    The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation

    Also known as: Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug

  • Combination productPlacebo 0.20 mg + 2.00 mg/kg

    Placebo 0.10 mg + 1.00 mg/kg

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Experiencing any Treatment-Emergent Adverse Events

    AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

    Time frame: First dose date up to Day 30 Follow-up Assessment

  2. Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities

    This will be assessed at various time points by clinical laboratory tests and vital signs.

    Time frame: First dose date up to Day 30 Follow-up Assessment

Secondary outcomes

  1. Maximum Concentration (Cmax) - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.

    Time frame: 7 days

  2. Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum

    Time frame: 7 days

  3. AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734

    Time frame: 7 days

  4. Area Under the Curve Extrapolated to Infinity (AUC0-∞)

    Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734

    Time frame: 7 days

  5. Half-Life (t1/2) - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.

    Time frame: 7 days

  6. Volume of Distribution (Vd) - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.

    Time frame: 7 days

  7. Clearance [CL] - Pharmacokinetic Assessment

    Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance \[CL\] of NA-831 and GS-5734 in human serum.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Coronavirus Research Institute
    Sunnyvale, California 94086, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — We plan to share the Study Protocol

Supporting information: Study protocol

Time frame: 90 days after the completion of the study

Access criteria: to be determined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2020; primary completion for Dec 2020, 3 months later.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 3 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 21, 2020
StartEst.
Sep 15, 2020
Primary completionEst.
Dec 31, 2020
CompletionEst.
Mar 31, 2021
Last update
Jul 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04480333
Lead sponsor
Biomed Industries, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Sep 15, 2020 (estimated)
Primary completion
Dec 31, 2020 (estimated)
Completion
Mar 31, 2021 (estimated)
Last update
Jul 21, 2020

Study contacts

Brian Tran, MD
Contact
BTran@neuroactiva.com
1-415-941-3133
Markku Kurkinen, PhD
Contact
MKurkinen@neuroactiva.com
1-415-941-3133
Lloyd Tran, PhD
study director · Biomed Industries, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: cyclo(prolylglycyl) · Remdesivir

Start the discussion